NCT03920735

Brief Summary

The analysis of a cohort of consecutive non-selected patients from the Strasbourg University Hospital, and therefore representative of the real life, will allow better identifying the risk factors for these infections (by comparison with a cohort of patient with similar conditions of immunosuppression and no infection) and improving the diagnosis and therapeutic management. The primary objective is to identify prognosis factors affecting survival in patients with opportunistic infections

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2017

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

August 6, 2018

Completed
9 months until next milestone

First Posted

Study publicly available on registry

April 19, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2019

Completed
Last Updated

April 19, 2019

Status Verified

September 1, 2018

Enrollment Period

2.3 years

First QC Date

August 6, 2018

Last Update Submit

April 15, 2019

Conditions

Outcome Measures

Primary Outcomes (4)

  • Short- and long-term survival, overall and in specific subgroups of patients

    Long-term time point : 1st may 2019

  • Short- and long-term survival, overall and in specific subgroups of patients

    Short term : 1 month

  • Short- and long-term survival, overall and in specific subgroups of patients

    Short term : 3 months

  • Short- and long-term survival, overall and in specific subgroups of patients

    Short term : 6 months

Secondary Outcomes (9)

  • Risk factors predisposing to opportunistic infections - age - gender - Type of work - Location - Tobacco use

    first day of opportunistic infection

  • Prognosis factors in patients with opportunistic infection affecting the response to antimicrobial therapy (using response criteria defined by EORTC/MSG)

    first day of opportunistic infection

  • Identification of baseline prognosis factors affecting the 3 months survival

    first day of opportunistic infection

  • Identification of baseline prognosis factors affecting the 6 months survival

    first day of opportunistic infection

  • Incidence of specific opportunistic infections in different host groups

    evolution of a 20-year-period

  • +4 more secondary outcomes

Study Arms (2)

Opportunistic infection

Immunocompromised or frail patients with an opportunistic infection

Control group

Immunocompromised or frail patients with no opportunistic infection

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients hospitalized in any department of the University Hospital of Strasbourg since 1997 Opportunistic infectious disease occurrence in immunocompromised or frail patients. In case of epidemiological study, patients from a control group with the same characteristics but without infection can be included.

You may qualify if:

  • Non selected consecutive immunocompromised or frail patients with an opportunistic infection
  • Hospitalized in any of the department of the University Hospital of Strasbourg
  • For epidemiological study, patients with similar immunodepression of frail condition and no opportunistic infection

You may not qualify if:

  • \- Opposition of the patient to use his personal data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital, Strasbourg, france

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Hematologic DiseasesImmunologic Deficiency SyndromesCritical Illness

Condition Hierarchy (Ancestors)

Hemic and Lymphatic DiseasesImmune System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Raoul HERBRECHT, MD

    University Hospital, Strasbourg, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2018

First Posted

April 19, 2019

Study Start

March 15, 2017

Primary Completion

July 15, 2019

Study Completion

July 15, 2019

Last Updated

April 19, 2019

Record last verified: 2018-09

Locations